CROI 2024：HIV 感染者中的结核病、猴痘和其他传染病并发症。
CROI 2024: Tuberculosis, Mpox, and Other Infectious Complications in People With HIV.
机构信息
University of California San Francisco, San Francisco, California, USA.
Columbia University, New York, New York, USA.
出版信息
Top Antivir Med. 2024 Jul 17;32(3):492-503.
Several novel antituberculosis agents, including long-acting injectable agents in mouse models, have shown promise in preclinical and early clinical studies. This encouraging news is offset by the failures of a tuberculosis (TB) vaccine to prevent disease recurrence and a 3-month clofazimine-based treatment regimen for drug-susceptible TB. Clinically focused insights regarding TB, mpox, and other HIV-associated infectious complications that were presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) are summarized in this review.
几种新型抗结核药物，包括在小鼠模型中具有长效注射作用的药物，在临床前和早期临床研究中显示出前景。这一令人鼓舞的消息被结核（TB）疫苗未能预防疾病复发以及对耐多药结核病采用的为期 3 个月氯法齐明为基础的治疗方案所抵消。在 2024 年逆转录病毒和机会性感染会议（CROI）上提出的关于结核、猴痘和其他与 HIV 相关的传染性并发症的临床重点研究结果在本综述中进行了总结。
Zotero 插件